Morphic Medical, Inc.
GIDYL
OTC PK
| Weiss Ratings | GIDYL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | GIDYL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | GIDYL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.00 | |||
| Price History | GIDYL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | 0.00% | |||
| 90-Day Total Return | 0.00% | |||
| Year to Date Total Return | 0.00% | |||
| 1-Year Total Return | 0.00% | |||
| 2-Year Total Return | 0.00% | |||
| 3-Year Total Return | 0.00% | |||
| 5-Year Total Return | -96.67% | |||
| 52-Week High % Change | 0.00% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | GIDYL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.00 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Apr 04, 2025 | |||
| 52-Week High Price (Date) | Apr 04, 2025 | |||
| Valuation | GIDYL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | -- | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | 0.00 | |||
| Earnings Per Share Growth | -100.00% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -- | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -0.96 | |||
| Enterprise Value/EBIT | -0.96 | |||
| Market Cap Category | -- | |||
| Dividends and Shares | GIDYL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 220.24B | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | GIDYL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 781 357 3300 | |||
| Address | 320 Congress Street Boston, MA 02210 | |||
| Website | morphicmedical.com | |||
| Country | United States | |||
| Year Founded | 2003 | |||
| Profitability | GIDYL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | GIDYL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -111.91% | |||
| Return on Equity | -- | |||
| Income Statement | GIDYL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -8.40M | |||
| EBIT (TTM) | -8.46M | |||
| Net Income (TTM) | -10.66M | |||
| Net Income Avl. to Common (TTM) | -10.66M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 16.61% | |||
| EPS Diluted (TTM) | 0.00 | |||
| EPS Diluted Growth (Q YOY) | -- | |||
| Balance Sheet | GIDYL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 931.00K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 3.59M | |||
| Total Preferred Equity (Q) | 0.78 | |||
| Total Equity (Q) | -1.26M | |||
| Current Ratio (Q) | 2.742 | |||
| Book Value Per Share (Q) | $0.00 | |||
| Total Assets (Q) | 3.80M | |||
| Total Current Liabilities (Q) | 1.31M | |||
| Total Debt (Q) | 4.15M | |||
| Total Liabilities (Q) | 5.06M | |||
| Total Common Equity (Q) | -2.03M | |||
| Cash Flow | GIDYL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 6.42M | |||
| Net Change in Cash (TTM) | -2.92M | |||
| Levered Free Cash Flow (TTM) | -7.45M | |||
| Cash from Operations (TTM) | -9.34M | |||
